Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

This study is testing whether adding venetoclax — a drug that helps trigger cancer cell death — to standard chemotherapy improves outcomes for older adults with newly diagnosed acute lymphoblastic leukemia (ALL), or for any adult whose ALL has returned or stopped responding to treatment. **You may be eligible if...** - You have ALL (a type of blood cancer) that has never been treated AND you are 60 years or older - OR you have ALL that has come back or stopped responding to prior treatment (any age) - Your bone marrow has at least 20% leukemia cells - Your organ function is adequate for chemotherapy **You may NOT be eligible if...** - Your leukemia is a different type (e.g., AML) - Your organ function is too poor to tolerate chemotherapy - You have active, uncontrolled infection Talk to your doctor to see if this trial is right for you.